Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pterygopalatine Fossa Block in aSAH
NCT05925478Phase 1Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Nov 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bupivacaine in aneurysmal subarachnoid hemorrhage (SAH), sponsored by UT Southwestern Medical Center. Primary endpoints: Opioid consumption at 3 days and Pain Rating Scale at 3 days. Started Nov 2023; status: completed.
02
Drugs
bupivacaine
03
Conditions
aneurysmal subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT05925478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05925478.